Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Quince Therapeutics is a late-stage biotech company developing innovative drug/device combination therapies using its proprietary AIDE platform, which encapsulates drugs into a patient’s own red blood cells for targeted, safer, and more effective treatment of rare diseases. Its lead candidate, eDSP, aims to treat neurodegenerative and autoimmune conditions like Ataxia-Telangiectasia, leveraging improved safety and biodistribution. The company focuses on clinical development, regulatory approval, and strategic partnerships in rare disease markets.
This description was generated via AI from an annual report. Updated about 1 year ago.